Free Trial

Helius Medical Technologies (HSDT) FDA Approvals

Helius Medical Technologies logo
$6.10 -0.81 (-11.72%)
Closing price 08/1/2025 04:00 PM Eastern
Extended Trading
$6.43 +0.33 (+5.41%)
As of 08/1/2025 07:54 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Helius Medical Technologies' Drug in the FDA Approval Process

This section highlights FDA-related milestones and regulatory updates for drugs developed by Helius Medical Technologies (HSDT). Over the past two years, Helius Medical Technologies has reported clinical trial outcomes, regulatory submissions, approvals, and other FDA events for drugs and therapies such as PoNS. For definitions of regulatory abbreviations such as NDA, BLA, or PDUFA, see the event status legend.

PoNS FDA Regulatory Timeline and Events

PoNS is a drug developed by Helius Medical Technologies for the following indication: Dynamic gait and balance deficits due to symptoms from stroke. This drug is under review by the U.S. Food and Drug Administration (FDA). Below is a timeline of key regulatory milestones for this therapy.

Helius Medical Technologies FDA Events - Frequently Asked Questions

As of now, Helius Medical Technologies (HSDT) has not received any FDA approvals for its therapy in the last two years.

In the past two years, Helius Medical Technologies (HSDT) has reported FDA regulatory activity for PoNS.

The most recent FDA-related event for Helius Medical Technologies occurred on July 21, 2025, involving PoNS. The update was categorized as "positive Outcome," with the company reporting: "Helius Medical Technologies, announced positive outcome from the PoNS (Portable Neuromodulation Stimulator) Stroke Registrational Program (SRP) supporting a planned FDA submission seeking an indication for gait and balance deficit in patients with chronic symptoms of stroke under the current Breakthrough Device Designation."

Currently, Helius Medical Technologies has one therapy (PoNS) targeting the following condition: Dynamic gait and balance deficits due to symptoms from stroke.

More FDA Event Resources from MarketBeat

  • NDA: New Drug Application
  • ANDA: Abbreviated New Drug Application
  • sNDA: Supplemental New Drug Application
  • BLA: Biologics License Application
  • sBLA: Supplemental Biologics License Application
  • FDA Approved: Approved by the FDA
  • EMA: European Medicines Agency
  • CE Mark: European Union Certification
  • NMPA: China National Medical Products Administration
  • MHLW: Japanese Ministry of Health
  • FDA Meeting: Consultation with FDA
  • Pre-IND: Pre-Investigational New Drug Meeting
  • Breakthrough Therapy: Special FDA designation for promising therapies
  • Fast Track: Accelerated FDA approval pathway
  • Orphan Drug: Designation for rare disease treatments
  • RPD: Rare Pediatric Disease Designation
  • RMAT: Regenerative Medicine Advanced Therapy
  • DSMB Review: Data Safety Monitoring Board Review
  • IDMC Review: Independent Data Monitoring Committee
  • MAA: MHRA Marketing Authorization Application
  • RTF: Refusal to File (Rejected Application)
  • 510(k): FDA Clearance for Medical Devices
  • Rolling Submission: Staggered regulatory review process

This page (NASDAQ:HSDT) was last updated on 8/2/2025 by MarketBeat.com Staff
From Our Partners